



Telix Pharmaceuticals Limited

ACN 616 620 369
55 Flemington Road
North Melbourne
Victoria, 3051
Australia

ASX RELEASE

Update on Financial Reporting Requirements

Melbourne (Australia) – 18 December 2023. Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) advises that the ASX no longer requires Telix to lodge quarterly cash flow and activities reports under Listing Rules 4.7B and 4.7C due to its record of positive net operating cashflows over the past reported 12 months.

The Company remains committed to providing its shareholders with regular updates on its financial performance and key business activities.

Telix will continue to lodge yearly preliminary final reports (Appendix 4E) and half yearly reports (Appendix 4D) within two months of the end of the relevant reporting period. Telix's next periodic report will be the preliminary final report and Annual Report for the period ending 31 December 2023. The Company will also transition to providing annual guidance with respect to its commercial and financial performance, in the financial year commencing 1 January 2024.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. Telix is headquartered in Melbourne, Australia with international operations in the United States, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical-stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on [LinkedIn](#).

Telix's lead imaging product, gallium-68 (⁶⁸Ga) gozetotide injection (also known as ⁶⁸Ga PSMA-11 and marketed under the brand name Illuccix[®]), has been approved by the FDA,¹ by the Australian Therapeutic Goods Administration (TGA),² and by Health Canada.³

Telix Investor Relations

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

This announcement has been authorised for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

©2023 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals and Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates (all rights reserved).

¹ Telix ASX disclosure 20 December 2021.

² Telix ASX disclosure 2 November 2021.

³ Telix ASX disclosure 14 October 2022.